Status:
COMPLETED
A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
A single 125 mg oral dose of the investigational compound PD-0332991 will be administered alone and after steady-state dosing of tamoxifen to determine if coadministration of tamoxifen alters the plas...
Eligibility Criteria
Inclusion
- Healthy male between the ages of 18 and 55 years of age inclusive
- Body mass index (BMI) between 17.5 and 30.5 kg/m2
- Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion
- a positive urine drug screen
- a supine systolic blood pressure \>140 mm Hg, or diastolic blood pressure \>90 mm H.
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT01821066
Start Date
April 1 2013
End Date
August 1 2013
Last Update
October 8 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511